A Retrospective Observational Study to Investigate the Clinical Impact of EOB-MRI in the Diagnosis of Liver Metastasis of Pancreatic Cancer in Japan - A Real-World Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 39,624
- 试验地点
- 1
- 主要终点
- Descriptive summary of patient characteristics in EOB-MRI and non-EOB-MRI group
研究概览
简要总结
This is an observational study in which data from people with cancer that has spread from the pancreas to the liver are collected and studied. These adults will include people who already received their usual treatment and who have had a certain type of imaging scan before the diagnosis of pancreatic cancer.
Metastatic pancreatic cancer is a cancer that starts in the pancreas, a gland that helps to digest food, and has spread to other parts of the body. Pancreatic cancer most commonly spreads to the liver (called liver metastasis). Gadoxetate sodium-enhanced magnetic resonance imaging (EOB-MRI) is a type of imaging technique that uses a specific dye called gadoxetate sodium to produce clearer images of the liver.
Participants with pancreatic cancer can be treated with surgery only if their cancer has not spread to other parts of the body. Therefore, it is important to find out if the cancer has spread to other parts of the body before performing surgery. To do this, different imaging scans such as exploratory laparoscopy and CE-CT are used. However, these tests have certain limitations, such as complicated procedures or, in some cases inaccurate results.
Some studies suggest that performing EOB-MRI along with a regular CT scan may improve the chances of finding out if pancreatic cancer has spread to the liver. This imaging technique is especially helpful in detecting smaller tumors that may be missed in other types of scan. However, more information is needed to better understand the impact of EOB-MRI in Japanese people under real-world conditions.
The main purpose of this study is to learn more about how using EOB-MRI helps in deciding the treatment options, how well the participants do, and how much does the use of medical care facilities costs.
The main information that researchers will collect in this study:
participant characteristics, including age, sex, whether they smoke or not, how well they can manage daily tasks, any other health problems they have, how advanced their cancer is, and if they have undergone laparoscopy
the length of time:
from the date of diagnosis of pancreatic cancer until a participant dies (called overall survival)
from the date of first treatment for pancreatic cancer until the cancer spreads of other organs
from the date of diagnosis of pancreatic cancer to starting the first treatment
from the date of first treatment for pancreatic cancer to starting the second treatment option
treatments that the participants have received, including anti-cancer drugs, radiation, and surgery
the number of hospital visits, use of healthcare facilities, and related costs.
The information in this study will be grouped based on the participants who had an EOB-MRI and those who had non EOB-MRI.
The data will come from the participants' information stored in a database called Medical Data Vision (MDV) in Japan. Data collected will be from January 2011 to October 2022.
Researchers will track individual patients' data for at least 1 year, until death, until there is no health record in the MDV for 2 months after treatment starts, or until the end of study.
In this study, only available data from health records are collected. No visits or tests are required as part of this study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients having at least one confirmed diagnosis of pancreatic cancer (identified by ICD-10 diagnosis code C25.x, without a suspicious diagnosis flag) during the patient selection period
- •Patients having at least one active treatment record after the 1st confirmed diagnosis of pancreatic cancer
- •Patients 18 years of age or older at the index date
- •Patients having any recorded CE-CT or EOB-MRI or MRI without EOB record during the baseline period
- •EOB-MRI stands for enhanced liver MRI using gadoxetate sodium as the contrast agent. In this type of MRI, gadoxetate sodium is used as a contrast agent in the visualization of the liver tumor.
- •EOB-MRI group will include patients who underwent EOB-MRI during the baseline period.
- •Non-EOB-MRI group will include patients who underwent CE-CT or MRI with contrast agent other than the gadoxetate sodium during the baseline period.
- •MRI, CE-CT and contrast agents are identified by using the nine-digit Japanese receipt code specified in the separate code list
排除标准
- •Patients with no confirmed diagnosis of pancreatic cancer (ICD-10 diagnosis code C25.x) in the below category of the disease name in the discharge summary until the 1st discharge date after the index date:
- •"ICD-10 code of disease name which input the most medical resources"
- •"ICD-10 name of disease behind hospitalization"
- •Patients with no active treatment within 3 months (90 days) from the con-firmed pancreatic cancer diagnosis date
- •Patients with no medical record in the MDV database within 1 month (30 days) from the index date
结局指标
主要结局
Descriptive summary of patient characteristics in EOB-MRI and non-EOB-MRI group
时间窗: Up to 12 years
Descriptive summary of treatment pathways in EOB-MRI and non-EOB-MRI group
时间窗: Up to 12 years
Descriptive summary of healthcare utilization patterns in EOB-MRI and non-EOB-MRI group
时间窗: Up to 12 years
Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group
时间窗: Up to 12 years
次要结局
- Descriptive summary of healthcare utilization pattern in EOB-MRI and non-EOB-MRI group within the subgroups of interest(Up to 12 years)
- Comparison of time to diagnosis of new metastases from the index date (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)(Up to 12 years)
- Comparison of time to first treatment pathway option from the pancreatic cancer diagnosis date (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)(Up to 12 years)
- Comparison of time to second treatment pathway option from the index date (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)(Up to 12 years)
- Descriptive summary of clinical outcomes in EOB-MRI and non-EOB-MRI group within the subgroups of interest(Up to 12 years)
- Descriptive summary of clinical outcomes across three index-year groups(Up to 12 years)
- Descriptive summary of healthcare utilization pattern across three index-year groups(Up to 12 years)
- Descriptive summary of patient characteristics in EOB-MRI and non-EOB-MRI group within the subgroups of interest(Up to 12 years)
- Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group within the subgroups of interest(Up to 12 years)
- Descriptive summary of patient characteristics across three index-year groups(Up to 12 years)
- Descriptive summary of treatment pathways across three index-year groups(Up to 12 years)
- Descriptive summary of healthcare costs across three index-year groups(Up to 12 years)
- Descriptive summary of the likelihood of open-close laparotomy in patients with confirmed diagnosis of pancreatic cancer who is intended the surgical intervention between those in the EOB-MRI group and non-EOB-MRI group(Up to 12 years)
- Comparison of overall survival (time from pancreatic cancer diagnosis date to death) (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)(Up to 12 years)